help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Franchimont, N.
Right arrow Articles by Canalis, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Franchimont, N.
Right arrow Articles by Canalis, E.
Endocrinology Vol. 138, No. 12 5248-5255
Copyright © 1997 by The Endocrine Society

ARTICLES

Interleukin-6 with Its Soluble Receptor Enhances the Expression of Insulin-Like Growth Factor-I in Osteoblasts1

Nathalie Franchimont2, Valerie Gangji, Deena Durant and Ernesto Canalis

Departments of Research and Medicine (N.F., V.G., D.D., E.C.), Saint Francis Hospital and Medical Center, Hartford, Connecticut 06105; and The University of Connecticut School of Medicine (E.C.), Farmington, Connecticut 06030

Address all correspondence and requests for reprints to: Ernesto Canalis, M.D., Department of Research, Saint Francis Hospital and Medical Center, 114 Woodland Street, Hartford, Connecticut 06105-1299.

Interleukin (IL)-6, a cytokine produced by skeletal cells and known to increase bone resorption, has mitogenic effects for bone cells, possibly by regulating the synthesis of other local factors. We tested the effects of IL-6 and its soluble receptor (IL-6sR) on the expression of insulin-like growth factor (IGF)-I and IGF-II in cultured osteoblast-enriched cells from fetal rat calvariae (Ob cells). IL-6 did not modify IGF-I messenger RNA (mRNA) levels, but when tested in the presence of IL-6sR, IL-6 at 1 to 100 ng/ml increased IGF-I transcripts by up to 3.2-fold after 24 h. IL-6sR caused a small increase in IGF-I mRNA levels when tested alone. IL-6 and IL-6sR increased immunoreactive IGF-I levels by 2.4-fold after 24 h and 6.4-fold after 48 h. Cycloheximide prevented, and indomethacin markedly decreased, the effect of IL-6 and IL-6sR on IGF-I mRNA levels, but hydroxyurea did not. IL-6 and IL-6sR did not alter the decay of IGF-I mRNA in transcriptionally arrested Ob cells, and the half-life of the predominant 6.5-kb IGF-I transcript was about 11 h in control and treated cells. In addition, IL-6 and IL-6sR increased the levels of IGF-I heterogeneous nuclear RNA. IL-11 also increased IGF-I mRNA levels, whereas oncostatin M and leukemia-inhibitory factor did not. In contrast to their effects on IGF-I, IL-6 and IL-6sR caused only a modest increase in IGF- II mRNA and polypeptide levels. In conclusion, IL-6, in the presence of IL-6sR, increases IGF-I synthesis in Ob cells; this effect may lead to a secondary increase in bone formation.




This article has been cited by other articles:


Home page
 DiabetesHome page
S. M. Nelson, P. M. Coan, G. J. Burton, and R. S. Lindsay
Placental Structure in Type 1 Diabetes: Relation to Fetal Insulin, Leptin, and IGF-I
Diabetes, November 1, 2009; 58(11): 2634 - 2641.
[Abstract] [Full Text] [PDF]

Home page
 JDRHome page
K. Iwasaki, M. Komaki, K. Mimori, E. Leon, Y. Izumi, and I. Ishikawa
IL-6 Induces Osteoblastic Differentiation of Periodontal Ligament Cells
Journal of Dental Research, October 1, 2008; 87(10): 937 - 942.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
M. KJAeR
Role of Extracellular Matrix in Adaptation of Tendon and Skeletal Muscle to Mechanical Loading
Physiol Rev, April 1, 2004; 84(2): 649 - 698.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
R. D. Devlin, Z. Du, V. Buccilli, V. Jorgetti, and E. Canalis
Transgenic Mice Overexpressing Insulin-Like Growth Factor Binding Protein-5 Display Transiently Decreased Osteoblastic Function and Osteopenia
Endocrinology, October 1, 2002; 143(10): 3955 - 3962.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. Vermes, J. J. Jacobs, J. Zhang, G. Firneisz, K. A. Roebuck, and T. T. Glant
Shedding of the Interleukin-6 (IL-6) Receptor (gp80) Determines the Ability of IL-6 to Induce gp130 Phosphorylation in Human Osteoblasts
J. Biol. Chem., May 3, 2002; 277(19): 16879 - 16887.
[Abstract] [Full Text] [PDF]

Home page
 J. Physiol.Home page
B. K. Pedersen, A. Steensberg, and P. Schjerling
Muscle-derived interleukin-6: possible biological effects
J. Physiol., October 15, 2001; 536(2): 329 - 337.
[Abstract] [Full Text] [PDF]

Home page
 JBJSHome page
C. Vermes, R. Chandrasekaran, J. J. Jacobs, J. O. Galante, K. A. Roebuck, and T. T. Glant
The Effects of Particulate Wear Debris, Cytokines, and Growth Factors on the Functions of MG-63 Osteoblasts
J. Bone Joint Surg. Am., February 1, 2001; 83(2): 201 - 201.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1997 by The Endocrine Society